Potential New Treatment Presents Shift in Care for Cardiac Patients

Video

Pending further research a new powerful pharmaceutical combination could make a significant difference in the treatment of patients with a left ventricular assist device.

Pending further research a new powerful pharmaceutical combination could make a significant difference in the treatment of patients with a left ventricular assist device.

Using what John Gorcsan III, MD, from UPMC called "intensive pharmacologic therapy," the trial showed using ACE inhibitors, angiotensin receptor blockers, beta blockers, aldosterone antagonists, and digoxin showed that many patients who had needed a pump to help their hearts function were able to have the pump removed. These results were considerably better than similar trials that had looked at ways to help this patient population.

Related Videos
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Robert Rosenson, MD | Credit: Cura Foundation
© 2024 MJH Life Sciences

All rights reserved.